We begin our research endeavors with a solid foundation for study design and methodology. We have conducted systematic reviews of the current state of computerized assessments, led focus groups with primary care physicians to learn about their confidence and methods for diagnosing brain disorders, and reviewed qualitative results from feasibility studies in primary care settings.
We believe all novel assessments should be backed with evidence-based support before being used in clinical care. We have performed several types of validation with our tasks with sensitivity and specificity analyses, concurrent validity analyses, neuroanatomical validity analyses, and validation in several language adaptations across the globe.
Studies aimed at discovering links between TabCAT and biomarkers play a crucial role in early detection and diagnosis, treatment monitoring over time, and predicting change over time. We have seen significant associations between our tests and Aβ-PET and tau-PET status, and continue to perform research in this exciting field.
We believe in health equity for all, and the need for accessible tools is growing. We continue to validate our tools in multiple language adaptations, examine social determinants of health, and explore neurocognitive disorders in underserved populations such as those experiencing homelessness.
Implementation of the TabCAT-BHA into primary care is a novel paradigm to improve the frequency and quality of patient evaluations for detecting cognitive impairment in non-specialty clinical settings.
In this exploratory study, the TabCAT Match is associated with disease severity and disability and cerebellar volumes in individuals with multiple sclerosis in Greece.
The TabCAT-BHA is useful for detecting cognitive impairment in older adults with age-related macular degeneration.
The TabCAT Rapid Naming task is an accurate, reliable, and ecologically valid measure of age-related word-finding decline.